Loading...
•
Dec 31, 2021
Castle Biosciences Q4 2021 Earnings Report
Announced financial results, demonstrating revenue growth and strategic acquisitions.
Key Takeaways
Castle Biosciences reported a 45% increase in revenue for Q4 2021 compared to the same period in 2020, with significant growth in total gene expression profile test reports delivered. The company's full-year revenue increased by 50% compared to 2020. They also successfully completed two acquisitions.
Revenues increased by 45% to $25.0 million compared to Q4 2020.
Total gene expression profile test reports delivered increased by 60% to 8,242.
Gross margin for the quarter was 77.6%, with an adjusted gross margin of 82.2%.
Net loss for the quarter was $(6.4) million, compared to $(4.9) million for the same period in 2020.
Forward Guidance
The Company anticipates generating between $115-120 million in total revenue in 2022, including expected revenue from the TissueCypher Barrett’s esophagus test.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...